Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 1, 2008, Pages 82-90

  Heutling, Dennis ^a,b   Schulz, Hasmik ^a   Nickel, Ingrid ^a   Kleinstein, Juergen ^a   Kaltwasser, Petra ^c   Westphal, Sabine ^a   Mittermayer, Friedrich ^d   Wolzt, Michael ^d   Krzyzanowska, Katarzyna ^e   Randeva, Harpal ^f   Schernthaner, Guntram ^e   Lehnert, Hendrik ^b,f,g  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^f UNIVERSITY HOSPITAL COVENTRY   (United Kingdom)

^g UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; C PEPTIDE; C REACTIVE PROTEIN; CHOLESTEROL; DIMETHYLARGININASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERANDROGENISM; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; METABOLIC PARAMETERS; NAUSEA; OUTCOME ASSESSMENT; OVARY POLYCYSTIC DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL;

EID: 38149040839     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-0842     Document Type: Article

References (62)

1. Azziz R, Marin C, Hoq L, Badamgarav E, Song P 2005 Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. J Clin Endocrinol Metab 90:4650-4658
2. Dunaif A 1997 Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 18:774-800
3. Legro RS, Kunselman AR, Dodson WC, Dunaif A 1999 Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84:165-169
4. Boulman N, Levy Y, Leiba R, Shachar S, Linn R, Zinder O, Blumenfeld Z 2004 Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab 89:2160-2165
5. Diamanti-Kandarakis E, Paterakis T, Alexandraki K, Piperi C, Aessopos A, Katsikis I, Katsilambros N, Kreatsas G, Panidis D 2006 Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod 21:1426-1431
6. Diamanti-Kandarakis E, Alexandraki K, Piperi C, Protogerou A, Katsikis I, Paterakis T, Lekakis J, Panidis D 2006 Inflammatory and endothelial markers in women with polycystic ovary syndrome. Eur J Clin Invest 36:691-697
7. Escobar-Morreale HF, Botella-Carretero JI, Villuendas G, Sancho J, San Millan JL 2004 Serum interleukin-18 concentrations are increased in the polycystic ovary syndrome: relationship to insulin resistance and to obesity. J Clin Endocrinol Metab 89:806-811
8. Vgontzas AN, Trakada G, Bixler EO, Lin HM, Pejovic S, Zoumakis E, Chrousos GP, Legro RS 2006 Plasma interleukin 6 levels are elevated in polycystic ovary syndrome independently of obesity or sleep apnea. Metabolism 55:1076-1082
9. Morin-Papunen L, Rautio K, Ruokonen A, Hedberg P, Puukka M, Tapanainen JS 2003 Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88:4649-4654
10. Gonzalez F, Thusu K, Abdel-Rahman E, Prabhala A, Tomani M, Dandona P 1999 Elevated serum levels of tumor necrosis factor - in normal-weight women with polycystic ovary syndrome. Metabolism 48:437-441
11. Kravariti M, Naka KK, Kalantaridou SN, Kazakos N, Katsouras CS, Makrigiannakis A, Paraskevaidis EA, Chrousos GP, Tsatsoulis A, Michalis LK 2005 Predictors of endothelial dysfunction in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 90:5088-5095
12. Meyer C, McGrath BP, Teede HJ 2005 Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. J Clin Endocrinol Metab 90:5711-5716
13. Orio Jr F, Palomba S, Cascella T, De Simone B, Di Biase S, Russo T, Labella D, Zullo F, Lombardi G, Colao A 2004 Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab 89:4588-4593
14. Paradisi G, Steinberg HO, Hempfling A, Cronin J, Hook G, Shepard MK, Baron AD 2001 Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 103:1410-1415
15. Diamanti-Kandarakis E, Spina G, Kouli C, Migdalis I 2001 Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J Clin Endocrinol Metab 86:4666-4673
16. Dagre A, Lekakis J, Mihas C, Protogerou A, Thalassinou L, Tryfonopoulos D, Douridas G, Papamichael C, Alevizaki M 2006 Association of dehydroepiandrosterone-sulfate with endothelial function in young women with polycystic ovary syndrome. Eur J Endocrinol 154:883-890
17. Meyer C, McGrath BP, Cameron J, Kotsopoulos D, Teede HJ 2005 Vascular dysfunction and metabolic parameters in polycystic ovary syndrome. J Clin Endocrinol Metab 90:4630-4635
18. Boger RH 2003 Association of asymmetric dimethylarginine and endothelial dysfunction. Clin Chem Lab Med 41:1467-1472
19. Bode-Boger SM, Muke J, Surdacki A, Brabant G, Boger RH, Frolich JC 2003 Oral L-arginine improves endothelial function in healthy individuals older than 70 years. Vasc Med 8:77-81
20. Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP 1998 Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 98:1842-1847
21. Lundman P, Eriksson MJ, Stuhlinger M, Cooke JP, Hamsten A, Tornvall P 2001 Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol 38:111-116
22. Stuhlinger MC, Oka RK, Graf EE, Schmolzer I, Upson BM, Kapoor O, Szuba A, Malinow MR, Wascher TC, Pachinger O, Cooke JP 2003 Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine. Circulation 108:933-938
23. Mittermayer F, Krzyzanowska K, Exner M, Mlekusch W, Amighi J, Sabeti S, Minar E, Muller M, Wolzt M, Schillinger M 2006 Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. Arterioscler Thromb Vasc Biol 26:2536-2540
24. Valkonen VP, Paiva H, Salonen JT, Lakka TA, Lehtimaki T, Laakso J, Laaksonen R 2001 Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 358:2127-2128
25. Bae SW, Stuhlinger MC, Yoo HS, Yu KH, Park HK, Choi BY, Lee YS, Pachinger O, Choi YH, Lee SH, Park JE 2005 Plasma asymmetric dimethylarginine concentrations in newly diagnosed patients with acute myocardial infarction or unstable angina pectoris during two weeks of medical treatment. Am J Cardiol 95:729-733
26. Krzyzanowska K, Mittermayer F, Wolzt M, Schernthaner G 2007 Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes. Diabetes Care 30:1834-1839
27. Pasquali R, Gambineri A 2006 Insulin-sensitizing agents in polycystic ovary syndrome. Eur J Endocrinol 154:763-775
28. Prager R, Schernthaner G, Graf H 1986 Effect of metformin on peripheral insulin sensitivity in non insulin dependent diabetes mellitus. Diabete Metab 12:346-350
29. Dandona P, Aljada A, Ghanim H, Mohanty P, Tripathy C, Hofmeyer D, Chaudhuri A 2004 Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin. J Clin Endocrinol Metab 89:5043-5047
30. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC 1985 Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419
31. Albareda M, Rodriguez-Espinosa J, Murugo M, de Leiva A, Corcoy R 2000 Assessment of insulin sensitivity and β-cell function from measurements in the fasting state and during an oral glucose tolerance test. Diabetologia 43:1507-1511
32. Vester B, Rasmussen K 1991 High performance liquid chromatography method for rapid and accurate determination of homocysteine in plasma and serum. Eur J Clin Chem Clin Biochem 29:549-554
33. Teerlink T, Nijveldt RJ, de Jong S, van Leeuwen PA 2002 Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem 303:131-137
34. Mittermayer F, Namiranian K, Pleiner J, Schaller G, Wolzt M 2004 Acute Escherichia coli endotoxaemia decreases the plasma l-arginine/asymmetrical dimethylarginine ratio in humans. Clin Sci (Lond) 106:577-581
35. Eid HM, Arnesen H, Hjerkinn EM, Lyberg T, Seljeflot I 2004 Relationship between obesity, smoking, and the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine. Metabolism 53:1574-1579
36. Stuhlinger MC, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, Reaven GM, Tsao PS 2002 Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 287:1420-1426
37. McLaughlin T, Stuhlinger M, Lamendola C, Abbasi F, Bialek J, Reaven GM, Tsao PS 2006 Plasma asymmetric dimethylarginine concentrations are elevated in obese insulin-resistant women and fall with weight loss. J Clin Endocrinol Metab 91:1896-1900
38. Cleland SJ, Petrie JR, Small M, Elliott HL, Connell JM 2000 Insulin action is associated with endothelial function in hypertension and type 2 diabetes. Hypertension 35:507-511
39. Vryonidou A, Papatheodorou A, Tavridou A, Terzi T, Loi V, Vatalas IA, Batakis N, Phenekos C, Dionyssiou-Asteriou A 2005 Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 90:2740-2746
40. Lakhani K, Hardiman P, Seifalian AM 2004 Intima-media thickness of elastic and muscular arteries of young women with polycystic ovaries. Atherosclerosis 175:353-359
41. Nanayakkara PW, Teerlink T, Stehouwer CD, Allajar D, Spijkerman A, Schalkwijk C, ter Wee PM, van Guldener C 2005 Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure. Kidney Int 68:2230-2236
42. Furuki K, Adachi H, Matsuoka H, Enomoto M, Satoh A, Hino A, Hirai Y, Imaizumi T 2006 Plasma levels of asymmetric dimethylarginine (ADMA) are related to intima-media thickness of the carotid artery. An epidemiological study. Atherosclerosis 191:206-210
43. Boger RH, Lentz SR, Bode-Boger SM, Knapp HR, Haynes WG 2001 Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e) inaemia in humans. Clin Sci (Lond) 100:161-167
44. Ziegler S, Mittermayer F, Plank C, Minar E, Wolzt M, Schernthaner GH 2005 Homocyst(e)ine-lowering therapy does not affect plasma asymmetrical dimethylarginine concentrations in patients with peripheral artery disease. J Clin Endocrinol Metab 90:2175-2178
45. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N 2001 Low-grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 86:2453-2455
46. Tarkun I, Arslan BC, Canturk Z, Turemen E, Sahin T, Duman C 2004 Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab 89:5592-5596
47. Harborne LR, Sattar N, Norman JE, Fleming R 2005 Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. J Clin Endocrinol Metab 90:4593-4598
48. Mohlig M, Spranger J, Osterhoff M, Ristow M, Pfeiffer AF, Schill T, Schlosser HW, Brabant G, Schofl C 2004 The polycystic ovary syndrome per se is not associated with increased chronic inflammation. Eur J Endocrinol 150:525-532
49. Krzyzanowska K, Mittermayer F, Kopp HP, Wolzt M, Schernthaner G 2004 Weight loss reduces circulating asymmetrical dimethylarginine concentrations in morbidly obese women. J Clin Endocrinol Metab 89:6277-6281
50. Orio Jr F, Palomba S, Cascella T, DeSimone B, Manguso F, Savastano S, Russo T, Tolino A, Zullo F, Lombardi G, Azziz R, Colao A 2005 Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study. J Clin Endocrinol Metab 90:6072-6076
51. Asagami T, Abbasi F, Stuelinger M, Lamendola C, McLaughlin T, Cooke JP, Reaven GM, Tsao PS 2002 Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism 51:843-846
52. Dierkes J, Westphal S, Luley C 1999 Serum homocysteine increases after therapy with fenofibrate or bezafibrate. Lancet 354:219-220
53. Yilmaz M, Bukan N, Ayvaz G, Karakoc A, Toruner F, Cakir N, Arslan M 2005 The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome. Hum Reprod 20:3333-3340
54. Kopp HP, Kopp CW, Festa A, Krzyzanowska K, Kriwanek S, Minar E, Roka R, Schernthaner G 2003 Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol 23:1042-1047
55. Kopp HP, Krzyzanowska K, Mohlig M, Spranger J, Pfeiffer AF, Schernthaner G 2005 Effects of marked weight loss on plasma levels of adiponectin, markers of chronic subclinical inflammation and insulin resistance in morbidly obese women. Int J Obes (Lond) 29:766-771
56. Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P 2004 Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 89:6068-6076
57. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G 2006 Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427-2443
58. Yasuda N, Inoue T, Nagakura T, Yamazaki K, Kira K, Saeki T, Tanaka I 2002 Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Biochem Biophys Res Commun 298:779-784
59. Lindsay JR, Duffy NA, McKillop AM, Ardill J, O'Harte FP, Flatt PR, Bell PM 2005 Inhibition of dipeptidyl peptidase IV activity by oral metformin in type 2 diabetes. Diabet Med 22:654-657
60. Isoda K, Young JL, Zirlik A, MacFarlane LA, Tsuboi N, Gerdes N, Schonbeck U, Libby P 2006 Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. Arterioscler Thromb Vasc Biol 26:611-617
61. Gonzalez F, Rote NS, Minium J, Kirwan JP 2006 Increased activation of nuclear factor κB triggers inflammation and insulin resistance in polycystic ovary syndrome. J Clin Endocrinol Metab 91:1508-1512
62. Yang TL, Chen MF, Luo BL, Xie QY, Jiang JL, Li YJ 2005 Fenofibrate decreases asymmetric dimethylarginine level in cultured endothelial cells by inhibiting NF-kappaB activity. Naunyn Schmiedebergs Arch Pharmacol 371:401-407